News
Hosted on MSN1mon
Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentimentAmgen's (AMGN) late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial. The company announced Monday that it has ...
MariTide, from the drug maker Amgen, is different from the other weight loss drugs as it also has a monoclonal antibody, which allows the medication to stay in the body longer, NBC News health and ...
"MariTide delivered strong efficacy, including sustained weight loss without a plateau in the 52-week phase 2 study and meaningful improvements in cardiometabolic risk factors, representing a ...
In the Phase 2 study, MariTide demonstrated up to ~20% average weight loss in people living with obesity without Type 2 diabetes (T2D) compared with 2.6% in the placebo arm, and up to ~17% average ...
Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 ...
Average weight loss for participants with diabetes was 17%, compared to 1.4% in the placebo group. NBC News reported that this places MariTide on par with Wegovy and Zepbound.
The company said its drug, MariTide, led to significant weight loss but high rates of side effects and discontinuations in a mid-stage trial. Amgen released initial data from that trial back in ...
Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 ...
Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial.The company announced Monday that it has ...
A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase 2 clinical trial. If approved, the drug, called MariTide, could make ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results